{
  "ticker": "ACL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961611",
  "id": "02961611",
  "pages": 26,
  "price_sensitive": false,
  "date": "20250624",
  "time": "1800",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l22ydrhdmkh4.pdf",
  "summary": "Here is the concise summary of material information from the ASX announcement:\n\n**Substantial Holder Notice (Form 603) for Australian Clinical Labs Limited (ACL.AX)**  \n- **Substantial Holder:** Macquarie Group Limited and its controlled entities  \n- **Date became substantial holder:** 19 June 2025  \n- **Total shares held:** 9,920,746 FPO shares (5.05% voting power)  \n- **Key entities holding shares:**  \n  - Macquarie Investment Management Australia Limited: 4,343,264 shares  \n  - Macquarie Bank Limited: 939,431 shares  \n  - Macquarie Investment Services Limited (as Responsible Entity): 136,096 shares  \n\n**Relevant interests:**  \n- Power to control voting/disposal across multiple Macquarie entities (detailed in Annexure A).  \n\n**Recent trading activity (selected material transactions):**  \n- **Macquarie Investment Management Global Limited (MIMGL):** Net purchases of ~332k shares at ~AUD 2.69 on 19 June 2025.  \n- **Macquarie Bank Limited (MBL):** Significant collateral receipts/returns in May-June 2025.  \n\n**Key takeaways:**  \n- Macquarie Group crossed the 5% disclosure threshold on 19 June 2025.  \n- Active trading by Macquarie entities in ACL shares over the prior months.  \n\n*Omitted:* Extensive annexures of non-material entity lists and minor transactional details.",
  "usage": {
    "prompt_tokens": 37070,
    "completion_tokens": 315,
    "total_tokens": 37385,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-24T08:26:41.554424"
}